Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
PF-431396 (PF431396) is a pyrimidine-based and selective dual inhibitor of PYK2 and FAK (focal adhesion kinase and proline-rich tyrosine kinase 2) with potential anti-osteoporotic activity. It inhibits PYK2/FAK with IC50s of 11 nM and 2 nM, respectively. PF 431396 acts by promoting osteoblast recruitment and activity, thus stimulating bone formation in ovariectomized rats. PF-431396 can be potentially used in treatment of osteoporosis.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
:J Biol Chem.2009 May 8;284(19):13193-201;J Biol Chem.2009 Aug 21;284(34):22865-77.
|
Molecular Formula |
C22H21F3N6O3S
|
|
---|---|---|
Molecular Weight |
506.5
|
|
CAS # |
717906-29-1
|
|
SMILES |
S(C([H])([H])[H])(N(C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1C([H])([H])N([H])C1C(C(F)(F)F)=C([H])N=C(N=1)N([H])C1C([H])=C([H])C2=C(C=1[H])C([H])([H])C(N2[H])=O)(=O)=O
|
|
InChi Key |
POJZIZBONPAWIV-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C22H21F3N6O3S/c1-31(35(2,33)34)18-6-4-3-5-13(18)11-26-20-16(22(23,24)25)12-27-21(30-20)28-15-7-8-17-14(9-15)10-19(32)29-17/h3-9,12H,10-11H2,1-2H3,(H,29,32)(H2,26,27,28,30)
|
|
Chemical Name |
N-Methyl-N-[2-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9743 mL | 9.8717 mL | 19.7433 mL | |
5 mM | 0.3949 mL | 1.9743 mL | 3.9487 mL | |
10 mM | 0.1974 mL | 0.9872 mL | 1.9743 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
PF-4618433 promotes osteogenesis of hMSC cultures. hMSC cultures were treated with PF-431396 (days 4-7) or with PF-4618433 (days 1-7), and alkaline phosphatase activity determined on day 7 (A and B, respectively).J Biol Chem.2009 May 8;284(19):13193-201. td> |
SPR analysis of PYK2 compound binding kinetics.J Biol Chem.2009 May 8;284(19):13193-201. td> |
A, molecular surface of the PYK2 in the active site region in complex with ATPγS (magenta). Critical side chains are labeled (ball and stick representation) with hydrogen bonds (dashed lines). B, active site of PYK2 bound to PF-431396 (magenta). Hydrophobic residues interacting with the sulfonamide group are shown in yellow.J Biol Chem.2009 May 8;284(19):13193-201. td> |